Chronic Lymphocytic Leukemia (CLL)
99
22
28
41
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
23 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.2%
15 terminated out of 99 trials
73.2%
-13.3% vs benchmark
5%
5 trials in Phase 3/4
56%
23 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 41 completed trials
Clinical Trials (99)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Targeting IRAK4 in Chronic Lymphocytic Leukemia
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma